Given the clear negative impact of NAE inhibitors on immune cells and cancer immunogenicity due to off-target effects, we decided to employ CRISPR/Cas9 to specifically target the Nedd8 gene in murine cancer cells for in vivo studies. The gene discussed is NEDD8; the disease is cancer.